Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Noile-Immune Biotech's selling, general, & admin. expense for the
three
months ended in Dec. 2025 was 円115.70 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was 円435.90 Mil.
Noile-Immune Biotech (TSE:4893) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Noile-Immune Biotech Selling, General, & Admin. Expense Related Terms
Noile-Immune Biotech Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for Noile-Immune Biotech's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noile-Immune Biotech Selling, General, & Admin. Expense Chart
TSE:4893 vs VRTX, REGN, RVMD: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, Noile-Immune Biotech's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noile-Immune Biotech Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Noile-Immune Biotech's Selling, General, & Admin. Expense falls into.
Noile-Immune Biotech Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円435.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of 円435.90 Mil mean?
Noile-Immune Biotech (TSE:4893) has a Selling, General, & Admin. Expense of 円435.90 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Noile-Immune Biotech and its competitors.
Is Noile-Immune Biotech's Selling, General, & Admin. Expense too high?
Noile-Immune Biotech's current Selling, General, & Admin. Expense is 円435.90 Mil. Overall, Noile-Immune Biotech has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Selling, General, & Admin. Expense compare to VRTX and REGN?
Noile-Immune Biotech's Selling, General, & Admin. Expense of 円435.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Noile-Immune Biotech and its competitors. Noile-Immune Biotech's current Selling, General, & Admin. Expense is 円435.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.24, compared to a current price of 円142.00 — trading 3249.1% above its estimated fair value. The current Selling, General, & Admin. Expense is 円435.90 Mil. Noile-Immune Biotech's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Selling, General, & Admin. Expense is 円435.90 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?
Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued.
The current stock price of 円142.00 is trading 3249.1% above its estimated GF Value™ of 円4.24.
GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.
Key valuation signals for TSE:4893:
Selling, General, & Admin. Expense: 円435.90 Mil
GF Value™: 円4.24 vs. price of 円142.00 (3249.1% above fair value)
No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
46GF Score
Get the complete analysis for TSE:4893
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4893 has been successfully added to your 
